Stocks began the new month of April on a weaker note, as investors struggled to digest stronger-than-expected manufacturing data for March, amid concerns the Federal Reserve might postpone rate cuts.
Eiger BioPharmaceuticals files for Chapter 11 bankruptcy protection. Plans to sell Zokinvy (lonafarnib) to Sentynl Therapeutics or up to $26.0 million. Potential bidders can submit competing bids.
Surrozen engages in a private placement, aiming to raise approximately $192.5 million in gross proceeds. Updates on SZN-043 Phase 1a trial reveal promising safety, tolerability, and effects on liver function.
EV market slowdown is beginning to show up in the numbers of the frontrunners in the industry, with China's BYD seeing a sharp Q-o-Q plunge in deliveries.
United Airlines Holdings is grappling with Boeing Co's delivery delays, reportedly prompting a call for pilots to take unpaid leave. This move reflects the broader impact of Boeing's production challenges on airlines' growth strategies post-Covid.
Data from Candel Therapeutics on CAN-3110, a promising viral immunotherapy for recurrent high-grade glioma. Discover survival rates and potential advancements in cancer treatment.
FDA clears Baxter's Novum IQ LVP & SYR infusion pumps with Dose IQ Safety Software, streamlining training & reducing cognitive burden. Explore enhanced safety features & EMR interoperability.
FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates a decision from EMA in Q4 2024.